OncoHealth, the leading digital health company dedicated to oncology, unveiled, today, a new real-world evidence dashboard that enables researchers to study the comparative effectiveness and market performance of immunotherapies. Powered by clinically rich, real-time, pan tumor immunotherapy data and combined with advanced analytics, DashIO™ provides researchers with the ability to query and visualize low-latency real-world data on immune checkpoint inhibitors.
“Immune checkpoint inhibitors are among the most promising and the fastest-growing drug class in oncology. This rapid growth has created a “wild west” of immunotherapy that has proven difficult for life sciences companies to track in both a timely and comprehensive manner,” said Steve Davis, President of Life Science at OncoHealth. “With real-world data captured at the time of diagnosis, DashIO enables pharmaceutical and biotech researchers to identify changes in drug and product performance faster than traditional approaches.”
Since 2020, 44% of the immune checkpoint inhibitor FDA approvals were combination therapies. DashIO is a comprehensive offering that includes near real-time data, reporting, and visualizations to facilitate the monitoring of the immunotherapy market landscape at the drug and regimen level. Along with longitudinal, HIPAA compliant de-identified, clinical and claims data, including drug regimen-level data with monotherapy and combination therapy, DashIO enables researchers to generate insights to such questions as: